JPMorgan Begins Coverage on Relay Therapeutics (RLAY) with Overweight

JPMorgan has initiated coverage of Relay Therapeutics (RLAY) with an overweight rating. This indicates the bank's belief that the stock will outperform the market averages. Coverage initiation often leads to increased trading volume and visibility in the market. This development may impact investor perceptions and interest in RLAY as analysts often influence investment decisions. An overweight rating suggests potential for significant growth and attractiveness for ordinary investors looking to diversify their portfolios.